摘要
目的分析布林佐胺治疗青光眼的临床效果及安全性。方法选取我院2016年1月至2016年12月收治的50例(96眼)青光眼患者,随机分为两组各25例。观察组(50眼)采用布林佐胺滴眼液治疗,对照组(46眼)采用马来酸噻吗洛尔滴眼液治疗。分析对比两组患者治疗前后的眼压、血压、心率、不良反应情况。结果两组患者治疗后的眼压均较治疗前明显降低(P<0.05)。治疗2周、4周、8周、12周后,观察组的眼压均明显低于对照组(P<0.05)。两组患者治疗前后的血压、心率比较差异均无统计学意义(P>0.05)。观察组的不良反应发生率为8%,明显低于对照组的32%(P<0.05)。结论采用布林佐胺治疗青光眼的效果良好,能够有效降低患者的眼压,而且不良反应少,值得临床推广应用。
Objective To analyze the clinical effect and safety of brinzolamide in the treatment of glaucoma. Methods 50 cases （96 eyes） of patients with glaucoma admitted to our hospital from January 2016 to December 2016 were selected and randomly divided into two groups, with 25 cases in each group. The observation group （50 eyes） was treated with brinzolamide eye drops, while the control group （46 eyes） was treated with timolol maleate eye drops. The intraocular pressure, blood pressure, heart rate before and after treatment and adverse reactions were analyze and compared between two groups. Results The intraocular pressure of both groups significantly decreased （P 〈0.05）. 2 weeks, 4 weeks, 8 weeks and 12 weeks after treatment, the intraocular pressure of observation group were significantly lower than those of control group （P〈0.05）. No statistical difference was found in the blood pressure and heart rate between two groups before and after treatment （P 〉0.05）. The incidence of adverse reactions of observation group was 8%, significantly lower than 32% of control group （P 〈0.05）. Conclusions Brindrazine in the treatment of glaucoma has good effect, and can effectively reduce patients＇ intraocular pressure with fewer adverse reactions, which is worthy of clinical promotion and application.
出处
《临床医学工程》
2017年第9期1237-1238,共2页
Clinical Medicine & Engineering
